Update: here is a link to the Ocata website. The start of a new era for what was formerly ACT.
It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself.
What’s been happening?
ACT recently did a notable 100:1 reverse split on its stock, opening it up to a whole new group of investors.
The company has also settled some previously lingering litigation and gotten new some new IP.
The latest development is a move to change the company’s name to Ocata Therapeutics. I asked Bob Lanza about the name changed and he told me that “Ocata is a native American (Huron) word for ‘medicine man’.”
I’m guessing we’ll be saying goodbye to the old logo (above) and I’ll be very curious to see the new one.
Investors following the stock expect some major additional developments in coming days/weeks, which could include a major new paper on the ACT clinical trials for macular degeneration.
It’s an exciting time for the company.
By way of disclosure, I have a relatively recently acquired small amount of stock (in it for the long haul) in the company. This blog is not intended as financial advice.